retatrutide type 2 diabetes phase 2 trial 2024 ESC 2024: improves lipid and cardiovascular risk profile in II Retatrutide—A Game Changer in Obesity

Cardiovascular Effects Dose-dependent increases in heart rate were observed with retatrutide: Heart rate increases peaked at approximately 24 weeks Gradually declined thereafter while remaining elevated above baseline This pattern is similar to that observed with other GLP-1 receptor agonists[4] The clinical significance of these heart rate changes requires further evaluation in larger and longer-term studies

New research details improved liver health and reduced heart disease risk.

A UConn Health researcher explains how her lab is focusing on how GLP-1 medications affect the brain and how they can be improved for the future

Calocurb natural GLP-1 activator, pre-meal appetite management

Methods Databases were searched for randomized controlled trials (RCTs), casecontrol, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery

Despite this being prominent in the news, the first medication mentioned by GPs and IMs when asked Which drugs for managing of patients living with obesity are you aware of, even if you have not prescribed them? was, in 54% of responses, the much older and less effective orlistat and its brand names Xenical and Alli (figure 1)